Iceni Pharmaceuticals specializes in developing cancer therapies by repurposing and reformulating existing drugs for new indications. This approach significantly reduces the cost and risk associated with the drug development process. The company's lead drug candidate, cilengitide, is a pentapeptide drug initially targeted for the treatment of multiple myeloma, a type of blood cancer. Cilengitide has an excellent safety profile and offers a novel mechanism of action compared to existing myeloma treatments. It is administered as a supplementary therapy in combination with existing medications, rather than replacing them. Previously, cilengitide underwent an extensive Phase III clinical development program by Merck Serono for the treatment of glioblastoma, a type of brain cancer. By leveraging drugs that have already been through extensive clinical trials, Iceni Pharmaceuticals aims to bring new treatments to patients more rapidly. This strategy not only benefits patients by providing quicker access to new therapies but also offers a de-risked investment opportunity for investors and licensees.

Keywords: cancer therapies, drug repurposing, drug reformulation, cilengitide, multiple myeloma, glioblastoma, clinical trials, safety profile, supplementary therapy, investment opportunity.